US priority review status for oral MS drug Cladribine

Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

US priority review status for oral MS drug Cladribine

Post by MSUK »

Image

German pharmaceutical and chemicals company Merck KGaA has announced that the U.S. Food and Drug Administration accepted a new drug application for its oral multiple sclerosis treatment Cladribine with a priority review designation, after Merck's initial submission was rejected last fall.

Priority review status is applied to drugs that have the potential to provide significant advances in treatment and means the FDA will complete its review in six months rather than the usual 10. Merck expects a decision in the fourth quarter....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Mavenclad (Cladribine)”